$CURR is now starting to benefit greatly from the
Post# of 24979
(Total Views: 166)
Posted On: 10/11/2022 11:46:16 AM
$CURR is now starting to benefit greatly from the $20 million sale of a small part of their IP assets in July. The September 2nd comments from new CEO Nancy Duitch put everything into perspective very well...
“I couldn’t be more pleased that the Company received the capital from the asset sale the last week in July, which will enable us to finally achieve our revenue and strategic goals within the next year. We are seeing positive results from our new marketing initiatives with increasing sales trends in the first six weeks of Q3 as we work to increase our revenues significantly in the second half and should see an additional acceleration in Q4. During Q2 we worked on successfully increasing our gross margins, while we continually work to decrease the SG&A. In anticipation of receipt of the non-dilutive capital, the team began working on the strategy to renew our advertising and marketing campaigns with Nutri-Strips and Seratopical Revolution lines, both of which have Cure’s proprietary delivery system technologies. I look forward to additional non-dilutive capital infusions and am very excited about the new technologies Rob Davidson and his team are working on for the Company,” says Nancy Duitch, Cure Pharmaceutical, CEO
Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins
https://www.globenewswire.com/en/news-release...rgins.html
“I couldn’t be more pleased that the Company received the capital from the asset sale the last week in July, which will enable us to finally achieve our revenue and strategic goals within the next year. We are seeing positive results from our new marketing initiatives with increasing sales trends in the first six weeks of Q3 as we work to increase our revenues significantly in the second half and should see an additional acceleration in Q4. During Q2 we worked on successfully increasing our gross margins, while we continually work to decrease the SG&A. In anticipation of receipt of the non-dilutive capital, the team began working on the strategy to renew our advertising and marketing campaigns with Nutri-Strips and Seratopical Revolution lines, both of which have Cure’s proprietary delivery system technologies. I look forward to additional non-dilutive capital infusions and am very excited about the new technologies Rob Davidson and his team are working on for the Company,” says Nancy Duitch, Cure Pharmaceutical, CEO
Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins
https://www.globenewswire.com/en/news-release...rgins.html
(0)
(0)Scroll down for more posts ▼